To the full analysis
HCA Healthcare stock: growth
HCAHCA Healthcare reported $75.6B in revenue for fiscal 2025, up 7.1% on the prior year, up 8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
5.9%
per year from 2006 to 2025, per share 9.1%
Earnings (Annual rate)
10.4%
per year from 2006 to 2025, per share 13.5%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 8.0% | 6.7% | 5.9% |
| Revenue per share | 16.6% | 12.7% | 9.1% |
| Earnings | 12.6% | 12.3% | 10.4% |
| Earnings per share | 20.9% | 18.3% | 13.5% |
| Free cash flow | 3.8% | 12.5% | no data |
| Free cash flow per share | 12.1% | 18.9% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $25.48B | $1.04B | −$20M |
| 2007 | $26.86B | $874M | −$48M |
| 2008 | $28.37B | $673M | $197M |
| 2009 | $30.05B | $1.05B | $1.43B |
| 2010 | $30.68B | $1.21B | $1.76B |
| 2011 | $32.51B | $2.47B | $2.25B |
| 2012 | $33.01B | $1.61B | $2.31B |
| 2013 | $34.18B | $1.56B | $1.74B |
| 2014 | $36.92B | $1.88B | $2.27B |
| 2015 | $39.68B | $2.13B | $2.36B |
| 2016 | $41.49B | $2.89B | $2.89B |
| 2017 | $43.61B | $2.22B | $2.41B |
| 2018 | $46.68B | $3.79B | $3.19B |
| 2019 | $51.34B | $3.51B | $3.44B |
| 2020 | $51.53B | $3.75B | $6.4B |
| 2021 | $58.75B | $6.96B | $5.38B |
| 2022 | $60.23B | $5.64B | $4.13B |
| 2023 | $64.97B | $5.24B | $4.69B |
| 2024 | $70.6B | $5.76B | $5.64B |
| 2025 | $75.6B | $6.78B | $7.69B |
Revenue by segment
How HCA Healthcare, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Managed Care And Other Insurers49%
- Managed Medicare18%
- Medicare15%
- Medicaid8%
- Managed Medicaid5%
- International2%
- Other3%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Managed Care And Other Insurers | $23.44B | $24.81B | $24.47B | $26.54B | $26.54B | $30.3B | $29.12B | $31.82B | $34.95B | $36.97B | 48.9% |
| Managed Medicare | $4.36B | $4.79B | $5.5B | $6.45B | $7B | $8.42B | $9.2B | $10.5B | $11.99B | $13.44B | 17.8% |
| Medicare | $8.9B | $9.48B | $9.83B | $10.8B | $10.42B | $10.45B | $10.45B | $10.59B | $10.78B | $11.27B | 14.9% |
| Medicaid | $1.6B | $1.63B | $1.36B | $1.57B | $1.97B | $2.29B | $2.64B | $3.61B | $4.68B | $5.91B | 7.8% |
| Managed Medicaid | $2.48B | $2.35B | $2.4B | $2.45B | $2.62B | $3.12B | $4B | $3.88B | $3.98B | $3.69B | 4.9% |
| International | $1.2B | $1.1B | $1.16B | $1.16B | $1.12B | $1.34B | $1.32B | $1.51B | $1.68B | $1.86B | 2.5% |
| Other | $0 | $0 | $1.97B | $2.36B | $1.88B | $2.84B | $3.51B | $3.07B | $2.54B | $2.46B | 3.3% |
| Total revenue | $41.49B | $43.61B | $46.68B | $51.34B | $51.53B | $58.75B | $60.23B | $64.97B | $70.6B | $75.6B | 100% |
Revenue by region
Where HCA Healthcare, Inc. generates its revenue.
- American Group35%
- Atlantic Group33%
- National Group28%
- Other4%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| American Group | $22.32B | $24.6B | $26.45B | 35% |
| Atlantic Group | $21.17B | $23.17B | $24.71B | 32.7% |
| National Group | $18.11B | $19.61B | $21.28B | 28.1% |
| Other | $3.38B | $3.22B | $3.17B | 4.2% |
| Total revenue | $64.97B | $70.6B | $75.6B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 5 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.